Can low estrogen and low free testosterone worsen energy production and body composition after menopause?

The transition through menopause marks a significant metabolic shift where declining sex hormones directly intersect with systemic metabolic regulators, impacting energy production and body composition.

Mechanistic pathways of energy decline

• Mitochondrial impairment: Estrogen loss directly impairs mitochondrial biogenesis, oxidative phosphorylation, and antioxidant capacity in skeletal muscle and adipose tissue. This leads to diminished cellular ATP production and elevated oxidative stress.
• Hormonal convergence: Free testosterone modulates mitochondrial biogenesis and substrate utilization. When its decline occurs alongside postmenopausal estrogen loss, cellular bioenergetics are directly compromised.
• Thyroid-mitochondrial axis: Thyroid hormones (particularly T3) are primary regulators of mitochondrial biogenesis, dynamics, and quality control. Suboptimal thyroid function compromises respiratory chain activity, slowing the metabolic pace and worsening overall mitochondrial dysfunction.

Dysregulation of body composition

• Adipose redistribution: Estrogen deficiency is the primary driver of visceral adiposity and sarcopenia (lean mass loss). An elevated testosterone-to-estradiol ratio further drives fat storage into visceral depots rather than subcutaneous sites.
• Metabolic efficiency: Compounding thyroid dysfunction reduces metabolic rate and efficiency, predisposing individuals to weight gain and altered lipid profiles.
• Impaired lipid oxidation: Mitochondrial dysfunction in adipose and muscle tissues reduces fat oxidation and energy expenditure, reinforcing a cycle of visceral fat accumulation and deteriorated body composition.

Bottom line

• Robust clinical and mechanistic evidence demonstrates that postmenopausal declines in estrogen and free testosterone converge with thyroid and mitochondrial dysfunction to impair cellular ATP production and accelerate adverse body-composition changes, such as sarcopenia and visceral adiposity.